Race Oncology (ASX:RAC) Discovers RCDS1 Mechanism of Action
Primary Mechanism of Action
Race Oncology has discovered that (E,E)-bisantrene (RCDS1) acts by binding to G4-DNA and RNA structures, differentiating it from traditional chemotherapeutics like doxorubicin.
Clinical and Commercial Implications
The discovery facilitates identifying responsive cancer types and synergistic drug combinations, streamlining regulatory submissions and partnering opportunities.
Next Steps
Race Oncology plans further preclinical studies, clinical trials, and publication of findings in scientific journals.
Executive Comments
CEO and Managing Director Dr Daniel Tillett stated, “The discovery (E,E)-bisantrene acts primarily by binding to G4-DNA and RNA structures, and not like the chemotherapeutic doxorubicin, fundamentally changes our thinking on how to best use this drug in the clinic. Bisantrene continues to surprise, and we look forward to building on this mechanism of action discovery in our future clinical and commercial plans.”
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
